Kevin Zhang's Zhihu Live — Discussing Titles: Who Holds Higher Authority, CEO or President?

Entered the internet industry in 1998; served as Vice President of Dangdang.com as one of its co-founders. Regular特邀 Human Resources Expert on Tianjin TV’s program 'If Not You, Then Who?'. Career Mentor at universities including China University of Political Science and Law, Beijing University of Posts and Telecommunications, University of International Business and Economics, and Beijing University of Chemical Technology. As a senior headhunter, serves as personal career and entrepreneurship advisor to numerous founders and senior executives. This is my third Zhihu Live. First, I’d like to thank my good friend Zhou Yuan—founder of Zhihu—for providing me with some initial ideas. This topic frequently arises when entrepreneurial peers consult me about organizational restructuring or hierarchical relationships. Readers who have long followed my articles are likely professionals who grew up within China’s internet industry. We’re already quite familiar with titles such as CEO, COO, CTO—and even other less-common ‘C-suite’ roles—or terms like Co-Founder and Partner, which regularly appear in our professional lives. So here’s the question: What are the fundamental differences among these titles in terms of rank? And what are their reporting relationships? In this third Zhihu Live, I’ll specifically discuss titles—specifically, who holds higher authority: the CEO or the President? Date: October 26, 2016, at 8:00 PM. During the session, I’ll provide an in-depth analysis of reporting hierarchies across corporate titles—and highlight some common pain points and misconceptions. Registration link Topics covered in this Live include: 1. Do you know the distinctions among Chairman, President, CEO, Executive Director, and General Manager? 2. Who wields greater authority—the various 'C-suite' executives (e.g., CFO, CMO) versus Senior Vice Presidents or Executive Vice Presidents? 3. What exactly are Founders and Co-Founders? 4. What does the title 'Partner' mean? In law firms, investment banks, venture capital firms, and consulting firms—who reports to whom: Partners or Vice Presidents?

Medtronic Appoints New President! Management Structure for Greater China Region Adjusted

On October 19, 2026, Medtronic filed an 8-K form with the U.S. Securities and Exchange Commission (SEC), disclosing a senior leadership reshuffle: Mike Marinaro assumed the role of President of Medtronic effective October 14, reporting directly to Geoff Martha, Chairman and Chief Executive Officer. Following this promotion, Marinaro continues to oversee Medtronic’s Medical Surgical business, its Americas operations, and Global Commercial Operations—and now additionally assumes supervisory responsibility for the Greater China region. Alex Gu (Yu-Shao Gu), Medtronic’s Global Senior Vice President and President of Greater China, remains responsible for day-to-day management of the China business. This means that while Medtronic retains its existing China management team, it has adjusted the Group-level oversight structure for Greater China operations. Medtronic stated to industry media that this appointment aims to strengthen the company’s management architecture and enhance coordination of responsibilities across key markets. # From Sales Manager to Global President Marinaro joined Medtronic in 2000 as a Regional Sales Manager, focusing initially on cardiovascular devices. He led the Cardiac Rhythm Management (CRM) business for approximately six years. In 2022, he became Head of Medtronic’s surgical robotics business, overseeing the Hugo robotic-assisted surgery system. In 2023, he was promoted to lead the broader Surgical business. Since 2024, his responsibilities have expanded further to encompass the full Medical Surgical portfolio, the Americas market, and Global Commercial Operations. His career spans cardiovascular implantables, surgical robotics, surgical equipment, and global sales management. Within Medtronic’s Medical Surgical portfolio are businesses including Surgery & Endoscopy and Acute Care Monitoring—selling products such as surgical staplers, energy-based surgical devices, surgical equipment, patient monitoring systems, and robotic-assisted surgery platforms. The Hugo surgical robot—previously under Marinaro’s leadership—is one of Medtronic’s most strategically invested platforms in recent years. Designed with a modular architecture and flexible robotic arm configurations, Hugo integrates closely with Medtronic’s existing minimally invasive surgical instruments and digital surgery platforms. # Annual Revenue of USD 36.364 Billion: Cardiovascular Business Remains Largest; Diabetes Business Divestiture Completed For fiscal year 2026 (ended April 24, 2026), Medtronic reported revenue of USD 36.364 billion, up approximately 8.4% from USD 33.537 billion in the prior fiscal year. By business segment, Cardiovascular remains Medtronic’s largest revenue contributor, followed by Neuroscience and Medical Surgical. In March 2026, Medtronic’s diabetes business, MiniMed, completed its initial public offering (IPO). On October 19, Medtronic further disclosed that it had finalized the spin-off of MiniMed via a share exchange arrangement, fully exiting its remaining equity stake. Medtronic’s long-term business portfolio is thus increasingly concentrated around three core areas: Cardiovascular, Neuroscience, and Medical Surgical. Within the Cardiovascular segment, fiscal year 2026 revenues were: Cardiac Rhythm Management & Heart Failure—USD 7.504 billion; Structural Heart & Aortic—USD 3.817 billion; Coronary & Peripheral Vascular—USD 2.656 billion.

Calumet Inc. EVP-CFO David Lunin Files Form 4 on October 19

2 days ago

Calumet Specialty Products Partners reported a Form 4 filing for Executive Vice President and CFO David Lunin regarding a transaction on October 19th.

Calumet Inc: EVP-CFO David Lunin Files Form 4 on October 19

Investing.com South Africa

Investing.com Canada

2026-10-22

Calumet Inc. EVP-CFO David Lunin Files Form 4 on October 19

Calumet Inc. EVP-CFO David Lunin Files Form 4 on October 19

FAQ